Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 July 2024
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 July 2024Published: 31 March 2021
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2024
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2021
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 21 April 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 4 March 2020
Irreversible electroporation for primary liver cancer (IPG664)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 November 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (IPG630)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 31 October 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Microwave ablation for treating liver metastases (IPG553)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 April 2016
Living-donor liver transplantation (IPG535)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 November 2015
Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 July 2013
Irreversible electroporation for treating liver metastases (IPG445)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 February 2013
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)Product type:GuidanceProgramme:Diagnostics guidancePublished: 29 August 2012
Cryotherapy for the treatment of liver metastases (IPG369)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 15 December 2010
Radiofrequency ablation for colorectal liver metastases (IPG327)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 December 2009
Ex-vivo hepatic resection and reimplantation for liver cancer (IPG298)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 April 2009
Microwave ablation of hepatocellular carcinoma (IPG214)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 March 2007
Radiofrequency-assisted liver resection (IPG211)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 February 2007
Laparoscopic liver resection (IPG135)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 July 2005
Photodynamic therapy for bile duct cancer (IPG134)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 July 2005
Radiofrequency ablation of hepatocellular carcinoma (IPG2)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 July 2003
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 March 2025
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selective internal radiation therapy for unresectable colorectal metastases in the liverStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Percutaneous Laser (Photo) Ablation of Liver TumoursStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Transarterial Chemoembolisation for inoperable hepatocellular carcinomaStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC